Anna Rydström
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Rydström has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Agatheeswaran Subramaniam
Division of Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications Jonas Larsson
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications- Jonas Larsson
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications Tariq Enver
Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden
2 shared publications- Abdul Ghani Alattar
Lund University, Lund, Sweden
1 shared publication - Abhishek Niroula
Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA
1 shared publication
Latest Publications
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7339-7351
Chemotherapy-related anemia is regulated through caspase-1–mediated ROCK1 activation
Hematopoietic stem cells (HSCs) have the ability to produce all cells in the blood system and are crucial for blood and immune recovery after chemotherapy. Patients with cancer often experience anemia, especially during chemotherapy treatment. Severe anemia may cause treatment disruption and is closely linked to a worse prognosis for the patient. We followed hematopoietic recovery in mice after chemotherapy treatment with 5-fluorouracil (5-FU) and found that erythrocyte recovery is delayed compared to other blood lineages. The delayed erythroid recovery manifests itself in HSCs that are transcriptionally and functionally biased toward myeloid cell production at the expense of erythropoiesis. We show that this erythroid deficiency is rescued in a caspase-1−/− mouse model, and that caspase-1 regulates lineage bias through an interleukin-1β–independent mechanism involving rho-associated coiled-coil–containing protein kinase 1 (ROCK1). Inhibiting the caspase-1 substrate ROCK1 leads to a rescue of erythropoiesis after 5-FU treatment. Indeed, we confirmed that ROCK1 is cleaved and activated by caspase-1 upon 5-FU treatment, suppressing erythropoiesis. Currently, patients with cancer who are anemic have limited treatment options for improving their red blood cell numbers. Several ROCK1 inhibitors have already been approved for use in other conditions and could potentially be used to mitigate anemia associated with cancer and chemotherapy, thereby improving quality of life and outcomes for patients with cancer.
- 30 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7339-7351
Chemotherapy-related anemia is regulated through caspase-1–mediated ROCK1 activation
Hematopoietic stem cells (HSCs) have the ability to produce all cells in the blood system and are crucial for blood and immune recovery after chemotherapy. Patients with cancer often experience anemia, especially during chemotherapy treatment. Severe anemia may cause treatment disruption and is closely linked to a worse prognosis for the patient. We followed hematopoietic recovery in mice after chemotherapy treatment with 5-fluorouracil (5-FU) and found that erythrocyte recovery is delayed compared to other blood lineages. The delayed erythroid recovery manifests itself in HSCs that are transcriptionally and functionally biased toward myeloid cell production at the expense of erythropoiesis. We show that this erythroid deficiency is rescued in a caspase-1−/− mouse model, and that caspase-1 regulates lineage bias through an interleukin-1β–independent mechanism involving rho-associated coiled-coil–containing protein kinase 1 (ROCK1). Inhibiting the caspase-1 substrate ROCK1 leads to a rescue of erythropoiesis after 5-FU treatment. Indeed, we confirmed that ROCK1 is cleaved and activated by caspase-1 upon 5-FU treatment, suppressing erythropoiesis. Currently, patients with cancer who are anemic have limited treatment options for improving their red blood cell numbers. Several ROCK1 inhibitors have already been approved for use in other conditions and could potentially be used to mitigate anemia associated with cancer and chemotherapy, thereby improving quality of life and outcomes for patients with cancer.
- Open Access
- 13 December 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (24) , 7407-7417
Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. To elucidate regulatory mechanisms governing the maintenance and propagation of human HSCs ex vivo, we screened libraries of annotated small molecules in human cord blood cells using an optimized assay for detection of functional HSCs during culture. We found that the antifungal agent ciclopirox ethanolamine (CPX) selectively supported immature CD34+CD90+ cells during culture and enhanced their long-term in vivo repopulation capacity. Purified HSCs treated with CPX showed a reduced cell division rate and an enrichment of HSC-specific gene expression patterns. Mechanistically, we found that the HSC stimulating effect of CPX was directly mediated by chelation of the intracellular iron pool, which in turn affected iron-dependent proteins and enzymes mediating cellular metabolism and respiration. Our findings unveil a significant impact of iron homeostasis in regulation of human HSCs, with important implications for both basic HSC biology and clinical hematology.
- 13 December 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (24) , 7407-7417
Open AccessCiclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. To elucidate regulatory mechanisms governing the maintenance and propagation of human HSCs ex vivo, we screened libraries of annotated small molecules in human cord blood cells using an optimized assay for detection of functional HSCs during culture. We found that the antifungal agent ciclopirox ethanolamine (CPX) selectively supported immature CD34+CD90+ cells during culture and enhanced their long-term in vivo repopulation capacity. Purified HSCs treated with CPX showed a reduced cell division rate and an enrichment of HSC-specific gene expression patterns. Mechanistically, we found that the HSC stimulating effect of CPX was directly mediated by chelation of the intracellular iron pool, which in turn affected iron-dependent proteins and enzymes mediating cellular metabolism and respiration. Our findings unveil a significant impact of iron homeostasis in regulation of human HSCs, with important implications for both basic HSC biology and clinical hematology.
- Open Access
- 4 September 2023
- Published by Elsevier in Experimental Hematology
- Vol. 127, 40-51
Functional and molecular profiling of hematopoietic stem cells during regeneration
- 4 September 2023
- Published by Elsevier in Experimental Hematology
- Vol. 127, 40-51
Open AccessFunctional and molecular profiling of hematopoietic stem cells during regeneration
- Open Access
- 14 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
GATA2 mitotic bookmarking is required for definitive haematopoiesis
In mitosis, most transcription factors detach from chromatin, but some are retained and bookmark genomic sites. Mitotic bookmarking has been implicated in lineage inheritance, pluripotency and reprogramming. However, the biological significance of this mechanism in vivo remains unclear. Here, we address mitotic retention of the hemogenic factors GATA2, GFI1B and FOS during haematopoietic specification. We show that GATA2 remains bound to chromatin throughout mitosis, in contrast to GFI1B and FOS, via C-terminal zinc finger-mediated DNA binding. GATA2 bookmarks a subset of its interphase targets that are co-enriched for RUNX1 and other regulators of definitive haematopoiesis. Remarkably, homozygous mice harbouring the cyclin B1 mitosis degradation domain upstream Gata2 partially phenocopy knockout mice. Degradation of GATA2 at mitotic exit abolishes definitive haematopoiesis at aorta-gonad-mesonephros, placenta and foetal liver, but does not impair yolk sac haematopoiesis. Our findings implicate GATA2-mediated mitotic bookmarking as critical for definitive haematopoiesis and highlight a dependency on bookmarkers for lineage commitment.
- 14 August 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-17
Open AccessGATA2 mitotic bookmarking is required for definitive haematopoiesis
In mitosis, most transcription factors detach from chromatin, but some are retained and bookmark genomic sites. Mitotic bookmarking has been implicated in lineage inheritance, pluripotency and reprogramming. However, the biological significance of this mechanism in vivo remains unclear. Here, we address mitotic retention of the hemogenic factors GATA2, GFI1B and FOS during haematopoietic specification. We show that GATA2 remains bound to chromatin throughout mitosis, in contrast to GFI1B and FOS, via C-terminal zinc finger-mediated DNA binding. GATA2 bookmarks a subset of its interphase targets that are co-enriched for RUNX1 and other regulators of definitive haematopoiesis. Remarkably, homozygous mice harbouring the cyclin B1 mitosis degradation domain upstream Gata2 partially phenocopy knockout mice. Degradation of GATA2 at mitotic exit abolishes definitive haematopoiesis at aorta-gonad-mesonephros, placenta and foetal liver, but does not impair yolk sac haematopoiesis. Our findings implicate GATA2-mediated mitotic bookmarking as critical for definitive haematopoiesis and highlight a dependency on bookmarkers for lineage commitment.
- Open Access
- 12 November 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 16432
Protein receptor-independent plasma membrane remodeling by HAMLET: a tumoricidal protein-lipid complex
A central tenet of signal transduction in eukaryotic cells is that extra-cellular ligands activate specific cell surface receptors, which orchestrate downstream responses. This ‘’protein-centric” view is increasingly challenged by evidence for the involvement of specialized membrane domains in signal transduction. Here, we propose that membrane perturbation may serve as an alternative mechanism to activate a conserved cell-death program in cancer cells. This view emerges from the extraordinary manner in which HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) kills a wide range of tumor cells in vitro and demonstrates therapeutic efficacy and selectivity in cancer models and clinical studies. We identify a ‘’receptor independent” transformation of vesicular motifs in model membranes, which is paralleled by gross remodeling of tumor cell membranes. Furthermore, we find that HAMLET accumulates within these de novo membrane conformations and define membrane blebs as cellular compartments for direct interactions of HAMLET with essential target proteins such as the Ras family of GTPases. Finally, we demonstrate lower sensitivity of healthy cell membranes to HAMLET challenge. These features suggest that HAMLET-induced curvature-dependent membrane conformations serve as surrogate receptors for initiating signal transduction cascades, ultimately leading to cell death.
- 12 November 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 16432
Open AccessProtein receptor-independent plasma membrane remodeling by HAMLET: a tumoricidal protein-lipid complex
A central tenet of signal transduction in eukaryotic cells is that extra-cellular ligands activate specific cell surface receptors, which orchestrate downstream responses. This ‘’protein-centric” view is increasingly challenged by evidence for the involvement of specialized membrane domains in signal transduction. Here, we propose that membrane perturbation may serve as an alternative mechanism to activate a conserved cell-death program in cancer cells. This view emerges from the extraordinary manner in which HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) kills a wide range of tumor cells in vitro and demonstrates therapeutic efficacy and selectivity in cancer models and clinical studies. We identify a ‘’receptor independent” transformation of vesicular motifs in model membranes, which is paralleled by gross remodeling of tumor cell membranes. Furthermore, we find that HAMLET accumulates within these de novo membrane conformations and define membrane blebs as cellular compartments for direct interactions of HAMLET with essential target proteins such as the Ras family of GTPases. Finally, we demonstrate lower sensitivity of healthy cell membranes to HAMLET challenge. These features suggest that HAMLET-induced curvature-dependent membrane conformations serve as surrogate receptors for initiating signal transduction cascades, ultimately leading to cell death.